금융 뉴스 허브
실시간 글로벌 금융 시장 뉴스 · 분석 · 인사이트
BREAKING주요 뉴스
Stocks Rise Pre-Bell as Traders Await Fed Policy Decision, Inflation Report, Big Tech Earnings
The benchmark US stock measures pointed higher before the opening bell Monday as traders gear up for...
Stock market today: Dow, S&P 500, Nasdaq futures rise ahead of busy week of earnings, Fed rate decision
Investors braced for a full earnings docket and the Federal Reserve's next policy decision this week...
British Pound: Stronger PMIs lean hawkish for BoE – Danske Bank
Danske Research Team notes UK flash PMIs strengthened in October, with the composite rising to 53.1 ...
Key deals this week: Option Care Health, PTC, Energy Transfer and more
‘Big Short’ investors split over the AI risk that matters most
Steve Eisman says Michael Burry may be looking at the wrong weakness in the artificial-intelligence boom.
Nvidia in talks to buy ‘open’ model startup Reflection AI: FT
Better Biotechnology ETF: First Trust FBT vs. VanEck BBH
VanEck's lower 0.35% expense ratio appeals to cost-conscious investors, while First Trust's $2.9 billion in assets and equal-weighted approach offer broader diversification across 30 biotech holdings.
Cliffs unit is said to proceed with Canada layoffs despite govt. ultimatum
Wall Street split on pioneering S&P 500 stock's price target
Wall Street analysts are split on the outlook of a stock that joined the S&P 500 only last year.
China passenger vehicle retail market slumps 24% in September
Dell (DELL) Has Outpaced the S&P 500 by a Wide Stretch. Will the AI-Fueled Run Continue?
Much of the recent growth for Dell Technologies Inc. (NYSE:DELL) has come through hardware sales, which is a lower-margin, high-volume avenue for the overall business. Bottom-line expansion in the fut ...
Warren Buffett warns of a reality check coming for stock investors
Warren Buffett has a name for what is happening in markets right now. Investors may want to hear it.
Flight disruptions growing after missile attack on Saudi airport
Better Healthcare ETF: VanEck's Biotech-Focused BBH vs. State Street's XPH Targeting Pharma
BBH concentrates on 25 large-cap biotech leaders, while XPH diversifies across 62 pharmaceutical holdings. Both charge 0.35% annually, but their five-year returns diverged significantly.
Philips investors’ move to probe company over 2021 recall denied by Dutch court